Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma

Results of the population-based PHAROS-registry

Simone Oerlemans, Djamila E Issa, Esther C van den Broek, Marten R Nijziel, Jan Willem W Coebergh, Floortje Mols, L. van de Poll-Franse

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Objectives
The increasing number of longer living patients with follicular lymphoma (FL) and serious side effects of treatment urged us to study the health-related quality of life (HRQoL) and persistent (treatment-related) symptoms in unselected patients after different treatment modalities and compare HRQoL of patients with a normative population.
Methods
The population-based Eindhoven Cancer Registry was used to select patients diagnosed with FL during 2004–2010. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a 1-yr interval. This questionnaire was also completed by an age- and sex-matched normative population (N = 580). Detailed data on treatment were extracted from the cancer registry and Population-based HAematological Registry for Observational Studies (PHAROS).ResultsOf the 181 patients who were invited, 148 responded (82%, T1). Patients treated with immunochemotherapy reported clinically relevant higher mean fatigue scores than those who underwent radiotherapy (P = 0.02). No differences were observed on the other HRQoL scales between treatment groups. Mean HRQoL scores were worse for FL patients treated with immunochemotherapy compared with a normative population (P < 0.01). A quarter to 50% of patients persistently reported to be slowed down, lethargic, or persistently worried about future health or was limited in social activities. Subsequently, patients reporting these symptoms/worries had a lower global health status/HRQoL.
Conclusion
Alertness for persistent symptoms that occur during and after treatment of FL patients is needed and may help to avoid lasting negative influence on their HRQoL.
Original languageEnglish
Pages (from-to)229-238
JournalEuropean Journal of Haematology
Volume93
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Follicular Lymphoma
Neoplasms

Cite this

@article{edd7190edb554217a428776cfb9ce83f,
title = "Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma: Results of the population-based PHAROS-registry",
abstract = "ObjectivesThe increasing number of longer living patients with follicular lymphoma (FL) and serious side effects of treatment urged us to study the health-related quality of life (HRQoL) and persistent (treatment-related) symptoms in unselected patients after different treatment modalities and compare HRQoL of patients with a normative population.MethodsThe population-based Eindhoven Cancer Registry was used to select patients diagnosed with FL during 2004–2010. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a 1-yr interval. This questionnaire was also completed by an age- and sex-matched normative population (N = 580). Detailed data on treatment were extracted from the cancer registry and Population-based HAematological Registry for Observational Studies (PHAROS).ResultsOf the 181 patients who were invited, 148 responded (82{\%}, T1). Patients treated with immunochemotherapy reported clinically relevant higher mean fatigue scores than those who underwent radiotherapy (P = 0.02). No differences were observed on the other HRQoL scales between treatment groups. Mean HRQoL scores were worse for FL patients treated with immunochemotherapy compared with a normative population (P < 0.01). A quarter to 50{\%} of patients persistently reported to be slowed down, lethargic, or persistently worried about future health or was limited in social activities. Subsequently, patients reporting these symptoms/worries had a lower global health status/HRQoL.ConclusionAlertness for persistent symptoms that occur during and after treatment of FL patients is needed and may help to avoid lasting negative influence on their HRQoL.",
author = "Simone Oerlemans and Issa, {Djamila E} and {van den Broek}, {Esther C} and Nijziel, {Marten R} and Coebergh, {Jan Willem W} and Floortje Mols and {van de Poll-Franse}, L.",
year = "2014",
doi = "10.1111/ejh.12335",
language = "English",
volume = "93",
pages = "229--238",
journal = "European Journal of Haematology",
issn = "1600-0609",
publisher = "Wiley-Blackwell",
number = "3",

}

Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma : Results of the population-based PHAROS-registry. / Oerlemans, Simone; Issa, Djamila E; van den Broek, Esther C; Nijziel, Marten R; Coebergh, Jan Willem W; Mols, Floortje; van de Poll-Franse, L.

In: European Journal of Haematology, Vol. 93, No. 3, 2014, p. 229-238.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma

T2 - Results of the population-based PHAROS-registry

AU - Oerlemans, Simone

AU - Issa, Djamila E

AU - van den Broek, Esther C

AU - Nijziel, Marten R

AU - Coebergh, Jan Willem W

AU - Mols, Floortje

AU - van de Poll-Franse, L.

PY - 2014

Y1 - 2014

N2 - ObjectivesThe increasing number of longer living patients with follicular lymphoma (FL) and serious side effects of treatment urged us to study the health-related quality of life (HRQoL) and persistent (treatment-related) symptoms in unselected patients after different treatment modalities and compare HRQoL of patients with a normative population.MethodsThe population-based Eindhoven Cancer Registry was used to select patients diagnosed with FL during 2004–2010. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a 1-yr interval. This questionnaire was also completed by an age- and sex-matched normative population (N = 580). Detailed data on treatment were extracted from the cancer registry and Population-based HAematological Registry for Observational Studies (PHAROS).ResultsOf the 181 patients who were invited, 148 responded (82%, T1). Patients treated with immunochemotherapy reported clinically relevant higher mean fatigue scores than those who underwent radiotherapy (P = 0.02). No differences were observed on the other HRQoL scales between treatment groups. Mean HRQoL scores were worse for FL patients treated with immunochemotherapy compared with a normative population (P < 0.01). A quarter to 50% of patients persistently reported to be slowed down, lethargic, or persistently worried about future health or was limited in social activities. Subsequently, patients reporting these symptoms/worries had a lower global health status/HRQoL.ConclusionAlertness for persistent symptoms that occur during and after treatment of FL patients is needed and may help to avoid lasting negative influence on their HRQoL.

AB - ObjectivesThe increasing number of longer living patients with follicular lymphoma (FL) and serious side effects of treatment urged us to study the health-related quality of life (HRQoL) and persistent (treatment-related) symptoms in unselected patients after different treatment modalities and compare HRQoL of patients with a normative population.MethodsThe population-based Eindhoven Cancer Registry was used to select patients diagnosed with FL during 2004–2010. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a 1-yr interval. This questionnaire was also completed by an age- and sex-matched normative population (N = 580). Detailed data on treatment were extracted from the cancer registry and Population-based HAematological Registry for Observational Studies (PHAROS).ResultsOf the 181 patients who were invited, 148 responded (82%, T1). Patients treated with immunochemotherapy reported clinically relevant higher mean fatigue scores than those who underwent radiotherapy (P = 0.02). No differences were observed on the other HRQoL scales between treatment groups. Mean HRQoL scores were worse for FL patients treated with immunochemotherapy compared with a normative population (P < 0.01). A quarter to 50% of patients persistently reported to be slowed down, lethargic, or persistently worried about future health or was limited in social activities. Subsequently, patients reporting these symptoms/worries had a lower global health status/HRQoL.ConclusionAlertness for persistent symptoms that occur during and after treatment of FL patients is needed and may help to avoid lasting negative influence on their HRQoL.

UR - http://hdl.handle.net/10411/20408

U2 - 10.1111/ejh.12335

DO - 10.1111/ejh.12335

M3 - Article

VL - 93

SP - 229

EP - 238

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 1600-0609

IS - 3

ER -